SCHEMBL1099734

SCHEMBL1099734

O=C1NC(=O)C(CNS(=O)(=O)c2cccc(Oc3ccc(Cl)c(Cl)c3)c2)N1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LGALS8 O00214 4/20 0.42
LGALS3 P17931 4/20 0.42
PGR P06401 4/20 0.41
PTGES2 Q9H7Z7 1/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 1/20 0.38
ADAMTS5 Q9UNA0 2/20 0.37
HTR2A P28223 1/20 0.37
SLC6A4 P31645 1/20 0.37
KCNH2 Q12809 1/20 0.37
KMO O15229 1/20 0.37
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
HRH1 P35367 1/20 0.35
CCR3 P51677 1/20 0.35
BCL2L1 Q07817 1/20 0.35
MCL1 Q07820 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1108479 1.00 LGALS8 (0.42) LGALS8LGALS3PGRPTGES2MEN1
SCHEMBL1100111 0.92 PGR (0.42) PGRMEN1LMNAGAAKMT2A
SCHEMBL1108510 0.92 PGR (0.42) PGRMEN1LMNAGAAKMT2A
SCHEMBL1101192 0.90 LGALS8 (0.41) LGALS8LGALS3PGRPTGES2MEN1
SCHEMBL1099759 0.86 PGR (0.49) PGRMEN1LMNAGAAKMT2A
SCHEMBL1100507 0.86 HTT (0.43) PGRMEN1LMNAKMT2APOLB
SCHEMBL1108543 0.86 HTT (0.43) PGRMEN1LMNAKMT2APOLB
SCHEMBL1100926 0.84 PGR (0.44) PGRPTGES2GAAADAMTS5MAPT
SCHEMBL1108519 0.84 PGR (0.44) PGRPTGES2GAAADAMTS5MAPT
SCHEMBL1100869 0.80 MMP1 (0.50) PGRPTGES2MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 US disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 US disclosed
EP-1370537-B1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2010-10-13 EP disclosed
US-7666892-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2010-02-23 US disclosed
US-20080262045-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-10-23 US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 US disclosed
EP-1370536-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
EP-1370537-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002074751-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273849-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 LGALS8 3434/4885LGALS3 3678/4885PGR 3527/4885
US-20080262045-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 LGALS8 3434/4885LGALS3 3678/4885PGR 3527/4885
US-20040138276-A1 Metalloproteinase inhibitors MMP9, MMP11, MMP7 LGALS8 2422/4885LGALS3 2767/4885PGR 2805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.